Lymphocyte phenotypes of peripheral blood from 32 SLE patients and 30 normal subjects were studied with 13 kinds of monoclonal antibodies using indirect immunofluorescence technique. The results showed that T4+, T8+, T3+ and T11+ cells decreased in active cases of SLE, while Ia+, IL2R1+ and PCA-1+ cells increased, other B-cell phenotypes (B1, B2, B4, IgM, IgG, IgD) showed no significant difference from those of the normal group. Thus, in inactive SLE after therapeutic management, the numbers of T3+, T11+, T4+, Ia+ and IL2R1+ cells no longer show any abnormality, but the numbers of T8+, PCA-1+ cells and the level of serum IgG are still higher than normal. From the above-mentioned results, it was shown that: 1. The key change in active SLE is the abnormality of immunoregulatory T cells, especially T4+ cells; 2. In active SLE, some of the T cells have been activated in vivo and these immunocompetent cells play an important role in immunoglobulin production of B cells; 3. The hyperactivity of humoral immunity is mainly related to the increase of PCA-1+ cells under the regulation of T cells; 4. Both the lymphocyte phenotypes and clinical features of SLE showed heterogeneity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Synergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo.
Anticancer Drugs
January 2025
Department of Pharmacy, Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo Medical University, Kobe.
Prostate cancer antigen-1/ALKBH3, a DNA/RNA demethylase of 3-methylcytosine, 1-methyladenine (1-meA), and 6-meA, was found in prostate cancer as an important prognostic factor. Additionally, 1-meA has been associated with other cancers. The ALKBH3 inhibitor HUHS015 was found to be effective against prostate cancer both in vitro and in vivo .
View Article and Find Full Text PDFParaneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
Handb Clin Neurol
March 2024
French Reference Center for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Lyon, France; Synaptopathies and Autoantibodies (SynatAc) Team, Institut MeLis, Inserm U1314, UMR CNRS 5284, University Claude Bernard Lyon 1, Lyon, France.
Article Synopsis
- Gynecologic and breast cancers are commonly linked to paraneoplastic neurologic syndromes, particularly the Yo syndrome, which involves severe cerebellar ataxia in women, especially around their 60s.
- Diagnosis of Yo syndrome hinges on identifying Yo antibodies in the patient's serum or cerebrospinal fluid and always correlates with an underlying tumor, typically ovarian or breast cancer.
- While understanding the immune mechanisms behind these syndromes is improving, effective treatments remain limited, and other rarer syndromes related to these cancers exhibit unique immune and genetic characteristics.
Leukocyte Telomere Length and the Risk of Prostate Cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study.
J Gerontol A Biol Sci Med Sci
March 2024
Department of Urology, the Chinese People's Liberation Army (PLA) General Hospital, Beijing, People's Republic of China.
Background: Previous observational studies have been controversial regarding the association of leukocyte telomere length (LTL) with prostate cancer (PCa) and benign prostatic hyperplasia (BPH).
Methods: First, we conducted an observational study utilizing UK Biobank data. The correlation between LTL and the risk of PCa and BPH was evaluated via multivariate-adjusted logistic regression.
CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Front Immunol
October 2023
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Background: Purkinje cytoplasmic autoantibody type 1 (PCA-1)/anti-Yo autoimmunity is a common high-risk paraneoplastic neurological disorder, traditionally attributed antigenically to cerebellar degeneration-related protein 2 (CDR2), predominantly affecting women with gynecologic or breast adenocarcinoma. Single-modality CDR2 testing may produce false-positive results. We assessed the performance characteristics of the more recently purported major PCA-1/Yo antigen, CDR2-like (CDR2L), side by side with CDR2, in a line blot format.
View Article and Find Full Text PDFAssociation between chromosome abnormities and prenatal diagnosis indicators screening in the second trimester of pregnancy.
Medicine (Baltimore)
September 2023
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
This study aimed to explore the prenatal indicators in the second trimester of pregnancy and their association with chromosome abnormities (CA) to guide decisions toward invasive diagnostic procedures. Pregnant women who underwent prenatal screening and underwent amniocentesis in the second trimester in our Hospital between June 2017 and February 2019 were included in this retrospective cohort study. The reason for amniocentesis in prenatal screening and diagnoses was extracted from the charts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!